Skip to main navigation menu Skip to main content Skip to site footer

Allocated and applied vaccines against Covid-19 by territorial entity in Colombia

Vacunas asignadas y aplicadas contra COVID-19 por entidad territorial en Colombia




Section
Research Article

How to Cite
Díaz Pinzón, J. E. (2021). Allocated and applied vaccines against Covid-19 by territorial entity in Colombia. Journal of Medicine and Surgery Repertoire, 30. https://doi.org/10.31260/RepertMedCir.01217372.1266

Dimensions
PlumX
license

   

Jorge Enrique Díaz Pinzón

    Jorge Enrique Díaz Pinzón,

    Ingeniero. Magister en Gestión de la Tecnología Educativa, Especialista en Administración de la Informática Educativa. Docente de matemáticas e Investigador.


    Introduction: to achieve the end of this pandemic, a vast majority of people of the world must be immune to the virus. The safest evidenced way of achieving this is through a vaccine. Objective: to show the progress of the doses assigned and applied during vaccination against SARS-COV-2 in the territorial entities of Colombia. Methodology: a cross-sectional study was used for this research. Data was obtained from the Ministry of Health and Social Protection website based on the national vaccination plan against COVID-19 in the period from February 17 to July 31 2021. Results: the territorial entities with the highest percentage of assigned doses were: Bogota (18.61), Antioquia (14.92), Valle del Cauca (8.82), Cundinamarca (6.03) and Santander (5. 07) and with the highest percentage of applied vaccination doses were: Boyaca (92.85), Buenaventura (92.82), Amazonas (89.03), Cundinamarca (88.22), and Nariño (87). Conclusion: it is relevant to continue increasing the allocation of doses of vaccines against SARS-COV-2 and the vaccine application capacity in the different territorial entities of Colombia, underlining the importance of completing the recommended vaccination courses, enabling the achievement of herd immunity in the country in the short term.


    Article visits 893 | PDF visits 400


    Downloads

    Download data is not yet available.
    1. Statistics and Research Coronavirus (COVID-19) Vaccinations [Internet]. Our World in Data; 2021 [Consultado 3 de agosto 2021]; Disponible en: https://ourworldindata.org/covid-vaccinations
    2. World Health Organization. COVID-19 vaccines [Internet]. World Health Organization; 2021 [Consultado 3 de agosto 2021]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
    3. World Health Organization. COVID-19 vaccine tracker and landscape [Internet]. World Health Organization; 2021 [consultado 3 ago 2021]; Disponible en: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
    4. Ramírez, JA. Vacunas para COVID-19. Respirar. 2020;12(1):3-5
    5. Center for Disease Control and Prevntion. Science Brief: Emerging SARS-CoV-2 Variants [Internet]. Center for Disease Control and Prevntion; 2021 [Consultado 3 agosto 2021]; Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html
    6. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID‑19 vaccine safety. Int J Mol Med. 2020;46(5):1599-1602. doi: 10.3892/ijmm.2020.4733
    7. Krause PR, Gruber MF. Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations. N Engl J Med. 2020;383(19):e107. doi: 10.1056/NEJMp2031373
    8. Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vac: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. J Infect Dis. 2019;220(1):46-56. doi: 10.1093/infdis/jiz070
    9. Puthumana J, Egilman AC, Zhang AD, Schwartz JL, Ross JS. Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Adminis¬tration. JAMA Intern Med. 2020;181(4):559-560. doi: 10.1001/jamainternmed.2020.7472
    10. Spinola SM, Zimet GD, Ott MA, Katz BP. Human Challenge Studies Are Un-likely to Accelerate Coronavirus Vaccine Licensure Due to Ethical and Practical Issues. J Infect Dis. 2020;222(9):1572-1574. doi: 10.1093/infdis/jiaa457
    11. Cataño J, Aguirre HD. Vacunación del adulto en tiempos de COVID-19. Corporación de Investigaciones Biológicas. 2020;1(2):1-8.
    12. Ministerio de Salud y Protección Social de Colombia. Plan de vacunación nacional contra COVID-19 [Internet]. Ministerio de Salud y Protección Social de Colombia; 2021 [Consultado 3 ago 2021]. Disponible en: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx
    13. Díaz Pinzón JE. Estimación de la prevalencia del COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):99–102. https://doi.org/10.31260/RepertMedCir.01217372.1115
    14. Díaz Pinzón JE. Análisis de los resultados del contagio del COVID-19 respecto a su distribución geográfica en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):60–64. https://doi.org/10.31260/RepertMedCir.01217372.1082
    15. Díaz Pinzón, J. E. (2021). Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra el SARS-COV-2 en Colombia. Repert Med Cir. 2021;30(Núm. Supl.1):41–45. https://doi.org/10.31260/RepertMedCir.01217372.1227
    Sistema OJS 3.4.0.5 - Metabiblioteca |